Abstract:ABSTRACTBackgroundChronic hepatitis B (CHB) remains incurable due to the immune system’s tolerance towards the hepatitis B virus (HBV) surface antigen (HBsAg). This study aimed to achieve a functional cure by breaking HBV tolerance through immunotherapy.MethodsCHB patients were treated with either standard nucleotide analog (NA) therapy (Adefovir Dipivoxil, ADV) (cohort 1) or ADV combined with interferon-alpha (IFN-alpha) (cohort 2). Additionally, a third cohort received the THRIL-GM-Vac regimen: three low-dose GM-CSF injections followed by one dose of the HBV vaccine, alongside standard treatment.ResultsTHRIL-GM-Vac treatment (cohort 3) achieved a significant 2log10 reduction in HBsAg levels in 21.7% of participants compared to 0% and 4.17% in cohorts 1 and 2, respectively. Furthermore, THRIL-GM-Vac significantly reduced HBV-specific tolerogenic T cells (Tregs), explaining the sustained HBsAg decrease. Upregulation of anti-HBV T cell responses confirmed THRIL-GM-Vac’s ability to disrupt HBV tolerance and enhance HBsAg-specific cellular immunity. This suggests its potential effectiveness in treating individuals with moderate to low HBsAg levels.ConclusionTHRIL-GM-Vac treatment in cohort 3 resulted in 8.7% HBsAg clearance alongside Treg depletion and enhanced anti-viral T cell responses. These findings present a promising strategy to overcome immunotolerance and potentially combat chronic HBV infection.Significance of This StudyWhat Is Already Known- Persistent viral replication in chronic HBV infection increases the risk of disease progression. Achieving virological suppression is crucial, yet patients with HBsAg still face adverse outcomes, like hepatocellular carcinoma (HCC).- The ideal treatment goal is a functional cure, or HBsAg loss, which significantly improves clinical outcomes.- Current treatments include Nucleos(t)ide analogs (NAs) and Interferon (IFNs), with NAs being potent in viral replication inhibition but less effective in HBsAg clearance. IFNs offer a modestly better HBsAg loss rate.- Combining NAs with IFNs or switching to IFNs has shown some improvement in HBsAg seroclearance in clinical trials.New Findings- Previous studies highlighted GM-CSF as potential vaccine adjuvants that boost antitumor and antiviral immunity. Our study demonstrates that a combination of GM-CSF therapy and HBV vaccination (THRIL-GM-Vac), along with ADV and IFN-α as standard treatment, significantly reduces HBsAg levels and enhances anti-HBsAg cell-mediated immunity compared to the standard treatments.- Specifics include a considerable decrease of HBsAg in 43.5% of patients, with 21.7% exhibiting a major reduction, including HBsAg seroclearance in 8.7% of participants. This response coincided with an increase in cellular immunity markers.Clinical Implications- The THRIL-GM-Vac strategy, when combined with conventional antiviral treatments, opens avenues for achieving a functional HBV cure in a more significant proportion of patients.- Our findings suggest that targeting Treg-dependent immunotolerance correlates with HBsAg reduction, providing a potential immune-surrogate endpoint to predict treatment efficacy.- This approach offers a promising direction for future research and treatment strategies to meet unmet medical needs in chronic HBV treatment.

Effect of GM-CSF in Combination with Hepatitis B Vaccine on Revacination of Healthy Adult Non-Responders.

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

Revaccination of Non- and Low- Responders after a Standard Three Dose Hepatitis B Vaccine Schedule

Strategies for Hepatitis B Booster Vaccination among Children: an 8-Year Prospective Cohort Study

Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice

Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization.

Hepatitis B Revaccination in Healthy Non-Responder Chinese Children: Five-Year Follow-Up of Immune Response and Immunologic Memory.

Response to supplementary vaccination with recombinant or plasma hepatitis B vaccine in healthy non-responding children

The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: a 5-year follow-up study.

Clearance of HBeAg and HBsAg of HBV in mice model by a recombinant HBV vaccine combined with GM-CSF and IFN-α as an effective therapeutic vaccine adjuvant

The One Year Effects of Three Doses of Hepatitis B Vaccine As a Booster in Anti-Hbs-negative Children 11–15 Years after Primary Immunization; China, 2009–2011

Enrichment of Ly6Chi Monocytes by Multiple GM-CSF Injections with HBV Vaccine Contributes to Viral Clearance in a HBV Mouse Model.

A Pilot Study on the Combined Therapy of Granulocyte-Macrophage Colony-Stimulating Factor and Hepatitis B Vaccine on Chronic Hepatitis B Virus Carrier Children.

[A Five-Year Observation on Efficacy of Revaccination in Children of Non-Response to Hepatitis B Vaccine].

The Response of Hepatitis B Vaccination on Seronegative Adults with Different Vaccination Schedules.

[Effect analysis on non-and-low response infants after revaccinated hepatitis B vaccine]

Efficacy of hepatitis B revaccination in non-and-hyporesponders to the vaccine

Comparison of the effect of two different doses of recombinant hepatitis B vaccine on immunogenicity in healthy adults

Immunological Effects of a 10-Μg Dose of Domestic Hepatitis B Vaccine in Adults

Granulocyte Colony Stimulating Factor Adjuvant Role on the Immunological Response to Hepatitis B Vaccine in Patients With Cirrhosis: A Double Blind Randomized Placebo Controlled Trial

Seroclearance of HBsAg in Chronic Hepatitis B Patients after a Tolerance Breaking Immuno-Therapy: GM-CSF, Followed by A Recombinant HBV Vaccine